Compare VABK & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VABK | CRBU |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.9M | 179.7M |
| IPO Year | 2013 | 2021 |
| Metric | VABK | CRBU |
|---|---|---|
| Price | $40.50 | $1.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 4.3K | ★ 979.7K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.62% | N/A |
| EPS Growth | ★ 12.70 | 3.64 |
| EPS | ★ 3.55 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.63 |
| Revenue Next Year | N/A | $10.93 |
| P/E Ratio | $11.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.56 | $0.71 |
| 52 Week High | $44.50 | $3.53 |
| Indicator | VABK | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 62.06 | 52.39 |
| Support Level | $38.17 | $1.70 |
| Resistance Level | $41.33 | $2.06 |
| Average True Range (ATR) | 0.55 | 0.12 |
| MACD | 0.26 | -0.00 |
| Stochastic Oscillator | 100.00 | 66.20 |
Virginia National Bankshares Corp is a bank holding company which is engaged in the commercial and retail banking business. The bank offers a range of banking and related financial services, including checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, certificates of deposit, individual retirement accounts and other depository services. Its segments include the Bank, VNB Trust and Estate Services, Sturman Wealth Advisors, and Masonry Capital. The Bank's commercial banking activities involve making loans, taking deposits and offering related services to individuals, businesses, and charitable organizations.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.